Physician profile
Yan Jin
NPI 1851977516
$9,466.82
in general payments reported to CMS, 2019-2025
25 companies · $2,915 in 2025
The $2,915 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $951 · 2022: $1,817 · 2023: $1,660 · 2024: $2,123 · 2025: $2,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,325 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,325.12 |
| Education | $373.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,961.83 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $1,068.98 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $1,015.70 | 2021-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $736.13 | 2022-2025 | |
| Janssen Biotech, INC. | $587.75 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $577.30 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $512.84 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $288.59 | 2021-2025 | Bimzelx |
| Pfizer INC. | $288.43 | 2022-2025 | |
| Biofrontera INC. | $281.02 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $241.02 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $240.21 | 2021-2025 | Anzupgo, Adbry |
| E.R. Squibb & Sons, L.L.C. | $237.13 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $226.70 | 2023-2024 | Vtama |
| Amgen INC. | $190.64 | 2021-2025 | Otezla, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $170.89 | 2023-2025 | |
| Botanix Sb INC | $135.19 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $124.99 | 2021 | |
| Mayne Pharma Commercial LLC | $122.36 | 2022-2023 | |
| Organon LLC | $117.03 | 2025 | Vtama |
| Almirall LLC | $101.20 | 2021-2025 | Klisyri |
| Verrica Pharmaceuticals INC. | $67.79 | 2023-2025 | Ycanth |
| Galderma Laboratories, L.P. | $65.67 | 2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.55 | 2022-2024 | Jublia, Siliq |
| Strata Skin Sciences, INC. | $45.88 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.